Advancing Risk Stratification in MASLD and MASH: Biomarkers, Machine Learning, and Noninvasive Tools

Nov 08 2026
Convention Center: Bluebird Ballroom 1A
8:00 AM - 9:30 AM
Captured/recorded session Recorded
CE Credits CE Credits

World Class Speakers

José M Mato

Abstract Presenter
JM

Winston Dunn

Abstract Presenter
Winston Dunn, MD, , FAASLD

Zobair M Younossi

Abstract Presenter
Zobair M Younossi, MD, MPH, FAASLD

Butros Fakhoury

Abstract Presenter
Butros Fakhoury, MD

Takao Miwa

Abstract Presenter
Takao Miwa, MD, PhD

Naim Alkhouri

Abstract Presenter
Naim Alkhouri

Sonali Paul

Moderator
Sonali Paul, MD, MS

Leon Adams

Moderator
Leon Adams, MBBS, PhD

Description

This session will highlight emerging approaches to identifying patients with steatotic liver disease who are at greatest risk for advanced liver disease and adverse outcomes. Presentations will explore the role of lipid biomarkers, body phenotype, alcohol exposure assessment, noninvasive diagnostic criteria, and adaptive machine-learning strategies. Together, these studies underscore the evolving role of precision risk stratification in MASLD, MASH cirrhosis, and clinical trial prescreening.

Presentations

8:00 AM - 8:15 AM
Convention Center - Bluebird Ballroom 1A
Recorded session

Elevated lipoprotein(a) levels characterize a discordant MASLD phenotype

José M Mato, PhD | Abstract Presenter
8:15 AM - 8:30 AM
Convention Center - Bluebird Ballroom 1A
Recorded session

SMART-MASH (Sequential Machine-learning Assessment for Risk Triage in MASH Cirrhosis): An Adaptive Sequential Machine Learning Strategy Using Point-of-Care Laboratories, Selective VCTE, and Selective ELF Testing for Cirrhosis Prescreening in MASLD Clinical Trials

Winston Dunn, MD, , FAASLD | Abstract Presenter
8:30 AM - 8:45 AM
Convention Center - Bluebird Ballroom 1A
Recorded session

Beyond Alcohol Self-Report: Phosphatidylethanol (PEth) Assessment Uncovers Clinically Significant Alcohol Exposure in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Zobair M Younossi, MD, MPH, FAASLD | Abstract Presenter
8:45 AM - 9:00 AM
Convention Center - Bluebird Ballroom 1A
Recorded session

Identifying Silent Progressors: Machine Learning Prediction of Major Adverse Liver Outcomes in an Early At-Risk SLD Population

Butros Fakhoury, MD | Abstract Presenter
9:00 AM - 9:15 AM
Convention Center - Bluebird Ballroom 1A
Recorded session

Lean phenotype identifies a high-risk group for major liver-related outcomes across steatotic liver disease subtypes

Takao Miwa, MD, PhD | Abstract Presenter
9:15 AM - 9:30 AM
Convention Center - Bluebird Ballroom 1A
Recorded session

Utility of Noninvasive Criteria in Identifying patients with MASH Cirrhosis for Clinical Trials

Naim Alkhouri | Abstract Presenter

Objectives

  • Describe emerging clinical, biochemical, and phenotypic markers associated with high-risk MASLD and steatotic liver disease subtypes, including lipoprotein(a), lean phenotype, and clinically significant alcohol exposure
  • Evaluate the utility of noninvasive tests and sequential risk-stratification strategies, including VCTE, ELF testing, and point-of-care laboratory-based algorithms, for identifying patients with MASH cirrhosis and major adverse liver outcome risk
  • Discuss ways in which machine-learning models can support clinical trial prescreening and early identification of silent progressors across the spectrum of steatotic liver disease

Copyright © 2026 American Association for the Study of Liver Diseases

AASLD 2026